A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria
Active, not recruitingCTIS2023-504124-26-00
AstraZeneca ABChronic Kidney Disease and High Proteinuria
Start: 2024-04-04Target: 323Updated: 2026-01-12